Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Study of ALTO-100 in Adults With Major Depressive Disorder (MDD)

Next Previous
X
Search
Trial Profile

An Open-Label Study of ALTO-100 in Adults With Major Depressive Disorder (MDD)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALTO-100 (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Alto Neuroscience

    • Most Recent Events

    • 13 Aug 2024 According to an Alto Neuroscience media release, Investor Day focused on ALTO-100 planned for Sept 9, 2024 and topline data expected in October 2024.
    • 08 Feb 2023 Status changed from active, no longer recruiting to completed.
    • 21 Oct 2022 Planned number of patients changed from 225 to 50.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top